Xcout IntelMariposa Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Mariposa Therapeutics among biotechnology companies — ranked by similarity to what Mariposa Therapeutics actually does, not by market-cap band.
Subscribe to see Mariposa Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Mariposa Therapeutics
Mariposa Therapeutics Ltd is a biotechnology company founded in 2019 and headquartered in Cardiff, United Kingdom. The company is dedicated to researching and developing innovative therapeutic solutions for keratin-related disorders. Its scientific efforts are supported by specialized research investments aimed at addressing rare skin and tissue conditions.
Mariposa Therapeutics at a glance
Mariposa Therapeutics is a biotechnology company headquartered in United Kingdom. Its most recent funding round, Seed, raised $995,400 in March 2026. Xcout tracks 7 named people at Mariposa Therapeutics, including Dr David Howat (Chief Executive Officer).
Mariposa Therapeutics leadership
- Dr David HowatChief Executive Officer
- Andres KorinChief Financial Officer
- Dr Lucy SykesChief Scientific Officer
- Carin BeumerChair of the Board
- Thomas HafnerFounder & Executive Director
- Damian MarronNon-Executive Director
1 more named person on record for Mariposa Therapeutics, with roles, board committees and tenure — see the full roster →
Mariposa Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $995,400 | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Mariposa Therapeutics competitors
Ranked by semantic similarity — how close each company is to Mariposa Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Similar biotechnology company
Eliksa Therapeutics, Inc. is a venture-backed biotechnology company based in Doylestown, Pennsylvania, specializing in regenerative medicine. The company focuses on developing innovative therapies to treat severe conditions such as Epidermolysis bullosa (EB). Through targeted research and funding, it works to advance clinical solutions for patients with rare genetic skin diseases.
Similar biotechnology company
Kamal Therapeutics, Inc. is a pharmaceutical holding company located in Hingham, Massachusetts, focused on developing treatments such as intravenous recombinant human decorin for dystrophic epidermolysis bullosa.
Similar biotechnology company
Pathios Therapeutics Limited is a biotech company established in 2017 and registered in England and Wales, focusing on the discovery and development of first-in-class therapies.
Similar biotechnology company
Palvella Therapeutics is a biotechnology company headquartered in Wayne, Pennsylvania, that specializes in developing and commercializing medicines for patients with rare dermatological diseases. The publicly traded company operates with corporate offices and an active team dedicated to clinical and commercial development.
Biotech
Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.
Biotech
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Similar biotechnology company
Nova Anchora is a San Francisco-based biopharmaceutical company founded in 2021 that develops advanced topical protein therapies for rare skin diseases. The company's lead product in development, NvA-011, is a recombinant version of collagen VII designed as a topical gel for the treatment of dystrophic epidermolysis bullosa.
Similar biotechnology company
Aldena Therapeutics is a biotechnology company focused on transforming dermatology through novel siRNA-based treatments for skin conditions.
Biotech
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Similar biotechnology company
Villaris Therapeutics was a clinical-stage biotechnology company developing antibody-based therapies for autoimmune and inflammatory skin diseases. Its intended beneficiaries were patients with immune-mediated dermatologic conditions.
Biotech
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Mariposa Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Mariposa Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →